Press releases
- METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
- TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
- Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
- Novocure Reports First Quarter 2024 Financial Results
- Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
- Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
- Novocure to Report First Quarter 2024 Financial Results
- Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
- METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
- INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
More ▼
Key statistics
As of last trade, Novocure Ltd (038:MUN) traded at 20.66, 96.11% above the 52 week low of 10.54 set on Nov 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 20.66 |
---|---|
High | 20.66 |
Low | 20.66 |
Bid | 19.84 |
Offer | 19.92 |
Previous close | 21.34 |
Average volume | 62.00 |
---|---|
Shares outstanding | 107.61m |
Free float | 97.65m |
P/E (TTM) | -- |
Market cap | 2.37bn USD |
EPS (TTM) | -1.81 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 07:05 BST.
More ▼